AACR 2014 - Pharmaco-imaging study of the effects of Debio1143, a new orally available IAP inhibitor, in a triple-negative breast cancer model

Centre Georges-François Leclerc, Oncodesign, Debiopharm International SA, ICMUB


By closing this message, you consent to our cookies on this device in accordance with our cookie policy unless you have disabled them.